What Could Go Right: Vital Partnerships with Communities and Civil Society for New Tuberculosis Vaccines, written together with community partners and supported by Wellcome, explores the indispensable role of communities and civil society in preparing the way for new TB vaccines and ensuring their success once they become available.
New tuberculosis (TB) vaccines could be realized as soon as 2028 — radically reshaping the journey to eliminate TB. Communities and civil society organizations are poised to play a vital role in the introduction of a future TB vaccine as central protagonists of this next chapter for TB elimination.
TAGLine 2025 documents a year of action as Treatment Action Group defended science, confronted attacks on public health, and fought to protect communities impacted by HIV, TB, and HCV.
Behind many lifesaving vaccines is a fragile supply chain that few people ever see. This new TAG report examines how weaknesses in the production and supply of key vaccine adjuvants (an ingredient that enhances the immune response) can create bottlenecks that threaten global access to vaccines, underscoring the importance of greater market transparency, security, and competitiveness among governments, funders, and pharmaceutical companies.
From Forest to Factory: Tracing the Supply Chains for Two Modern Adjuvants of Global Health Importance — QS-21 and MPL provides a first of its kind analysis of the global supply chains of two key adjuvants used in several of the world’s most important vaccines.
Public financing and domestic resources for health are straining under debt burdens as countries struggle to build up domestic revenues in the face of weak tax systems and volatile markets.
Treatment Action Group (TAG) is profoundly disappointed and outraged at the lack of healthcare protections for people living with and affected by HIV, tuberculosis (TB), and hepatitis C (HCV) in the bill to end the US government shutdown.
Treatment Action Group (TAG) welcomes the report published today by the World Health Organization TB Vaccine Accelerator Council on how to finance global, equitable access to new TB vaccines.
TAG and the Community Research Advisors Group (CRAG) are happy to introduce the TB Representative Studies Rubric (TB RSR), a new tool that community advisory boards (CABs) can use when designing and reviewing clinical trials protocols. The TB RSR is a 17-item questionnaire that assesses whether TB treatment trials include the types of people who get TB.
Treatment Action Group (TAG) opposes in the strongest possible terms the suspension of at least 22 TB research awards by the National Institutes of Health (NIH) following a May 2025 White House executive order banning “gain-of-function” research.